These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16675450)

  • 1. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
    Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
    Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
    Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A
    J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
    Voisset C; de Beeck AO; Horellou P; Dreux M; Gustot T; Duverlie G; Cosset FL; Vu-Dac N; Dubuisson J
    J Gen Virol; 2006 Sep; 87(Pt 9):2577-2581. PubMed ID: 16894196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.
    Zeisel MB; Koutsoudakis G; Schnober EK; Haberstroh A; Blum HE; Cosset FL; Wakita T; Jaeck D; Doffoel M; Royer C; Soulier E; Schvoerer E; Schuster C; Stoll-Keller F; Bartenschlager R; Pietschmann T; Barth H; Baumert TF
    Hepatology; 2007 Dec; 46(6):1722-31. PubMed ID: 18000990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.
    Voisset C; Callens N; Blanchard E; Op De Beeck A; Dubuisson J; Vu-Dac N
    J Biol Chem; 2005 Mar; 280(9):7793-9. PubMed ID: 15632171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.
    Catanese MT; Ansuini H; Graziani R; Huby T; Moreau M; Ball JK; Paonessa G; Rice CM; Cortese R; Vitelli A; Nicosia A
    J Virol; 2010 Jan; 84(1):34-43. PubMed ID: 19828610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.
    Dreux M; Dao Thi VL; Fresquet J; Guérin M; Julia Z; Verney G; Durantel D; Zoulim F; Lavillette D; Cosset FL; Bartosch B
    PLoS Pathog; 2009 Feb; 5(2):e1000310. PubMed ID: 19229312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
    Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
    J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
    Wasilewski LN; Ray SC; Bailey JR
    J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
    Bartosch B; Verney G; Dreux M; Donot P; Morice Y; Penin F; Pawlotsky JM; Lavillette D; Cosset FL
    J Virol; 2005 Jul; 79(13):8217-29. PubMed ID: 15956567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.
    Zahid MN; Turek M; Xiao F; Thi VL; Guérin M; Fofana I; Bachellier P; Thompson J; Delang L; Neyts J; Bankwitz D; Pietschmann T; Dreux M; Cosset FL; Grunert F; Baumert TF; Zeisel MB
    Hepatology; 2013 Feb; 57(2):492-504. PubMed ID: 23081796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
    Grove J; Nielsen S; Zhong J; Bassendine MF; Drummer HE; Balfe P; McKeating JA
    J Virol; 2008 Dec; 82(24):12020-9. PubMed ID: 18829747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.